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Bright yellow fluorescence of tumor tissue,
under long-wave ultraviolet light, after tetra-
cycline administration was first reported by
Hall and co-workers in 1957 (1), and was con-
firmed by McLeay in 1958 (2). They found that
the fluorescent material, a tetracycline complex,
was retained in experimental tumors in mice
and rats for as long as 10 to 20 days, while it
disappeared after 24 hours from the liver and
intestines of the injected animals. The phe-
nomenon has since been applied to the study of
neoplastie lesions in various locations, using it
as a tool for identification of cancerous tissue
in fresh non-fixed specimens. The observations
published to date are based on the detection of
fluorescence in gross and microscopical material
and indicate that tetracycline is deposited in
carcinomas and sarcomas (3—15). With the ex-
ception of one study (6), which involved visual
estimation of the intensity of fluorescence of
gastric aspirates, the data available are of a
qualitative nature.
The diagnostic value of this phenomenon has
been debated. Yellow-orange fluorescence is not
rare in gastric sediment from patients who
have not received tetracyline (13, 16). Tissue
fluorescence after tetracycline administration
has also been observed in chronic inflamma-
tions, e.g. experimental granuloma pouch (17),
in acute necrosis of the pancreas (18), in myo-
eardial infarction (19), in burns (18), in non-
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specific cutaneous ulcers (4, 12, 20), and in
palmnr pustules (21). Thus, Aberle has aptly
described the situation: " . . . all that fluoresces
is not tetracycline, nor is it necessarily carci-
noma" (16). All reports, however, agree that
preferential accumulation of tetracycline takes
place in tumorous tissue. Some workers believe
that the drug is taken up by cancer cells (22,
23), while others believe that it accumulates in
the maerophages and tissue debris of the tumor
stroma (4, 17). There is no agreement con-
cerning the nature of the tetracycline complex
and whether it occurs inside or outside of the
cells. Du Buy and Showacre (23) found that
tetracycline specifically combined with mito—
chondria of living cells, while Loo and co-
workers (22) found that it eomplexed with in-
tracellular peptides, and Lock ct at. (17) found
that it was bound ivith cellular and extraccllular
proteins. Furthermore, there is evidence that
precipitation of a lipo-protein-tetracychne com-
plex occurs in the presence of calcium ions (24,
25) or sulfated mueopolysaecharides (21).
In this study the mechanism of fluorescence
produced by tetracycline hydrochloride (TC),
in 7, 12-dimethyl (a) benzanthracene (DMBA)
induced tumors of rat skins, was evaluated by
fluorescence microscopy and speetrophotofluo-
rometric skin analysis. The purpose of the in-
vestigation was two-fold: 1) to determine quan-
titatively the affinity of TC for tumor tissue
by assessing the ability of squamous cell car-
einoinas to remove TC from the blood and re-
tain it as compared with liver and kidney; and
2) to determine by fluorescence microscopy
whether this TC uptake is primarily in the
cells of the tumor or in its stroma.
MATERIALS AND METII0n5
Experimental protocol. Using the method de-
scribed by Zaekheim (26, 28), skins of hooded
Long-Evans rats were painted with 0.5% dimeth-
ylbeazanthracene for 6 months to produce squa-
mous cell carcinomas. One drop of carcioogen in
acetone (0.1—02 ml) was applied weekly with a
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pipette to the unshaved midback of each rat in
the inter-scapular area. Treated rats were two
months old at onset of treatment and were equally
divided as to sex.
Fourteen rats, which developed tumors, were in-
jected intraperitoneally (I.P.) with 60 mg/Kg of
TC and 7 of these received a second dose of 40
mg/Kg 24 hours later. Three additional tumor rats
and three normal rats did not receive TC and
were used as controls. Three normal rats injected
with TC were also studied. Groups of animals
were sacrificed at various times post-injection for
blood and tissue studies. Two groups of two rats
each were exsanguinated at 5 and 24 hours and
two groups, of 5 rats each, at 48 and 72 hours.
Blood specimens were obtained (under light ether
anesthesia) by slow aspiration of inferior vena
eavae with heparinized syringes and immediately
analyzed for TC content. Livers, kidneys and tu-
mors were rapidly removed and frozen at minus
20° C until assays and microscopy could be per-
formed. Immediately prior to analysis, tissues were
shaved into thin slices while frozen, weighed on a
Roller-Smith micro-balance and homogenized in
cold 0.134 N HC1, using a Virtis Model 45 Homog-
euizer or a ground-glass test tube with motor
driven ground-glass pestle.
Fluorescence microscopy of tissues. Tumor ma-
terial was obtained from 14 rats both before and
after TC treatment and from three untreated
animals. Frozen sections (6 and 20 t) were ex-
amined by a Zeiss Photomicroseope using a high-
pressure mercury bulb (HBO 200 W). Filters em-
ployed were a BG12 excitation filter (spectral
transmission: 330—500 mp; maximal at 400 mL)
and a *t53 barrier filter (spectral transmission:
530 mz and longer wave1engtbs). Under this opti-
cal system TC fluoresces bright yellow. Sections
were examined both with lightfield and darkfield
techniques. High Speed Ektachrome (R) film(Daylight Type) was used in the camera.
A rapid staining technique was adopted for the
purpose of tissue identification and for the detec-
tion of site of localization of the fluorescent ma-
terial. After recording the fluorescent picture, the
microscope stage was locked in place and the
slide was removed. The section was then fixed in
absolute alcohol for 1 mm., air-dried, stained with
0.1% toluidine blue in 1% borax solution fer 20
see., washed with acetone, immersed in acetone for
1 mm., passed through xylene for 1—2 mm., and
then mounted. The slide was replaced on the
microscope stage and the field repbotographed,
using tungsten light and a conversion filter for
daylight type film.
Quentitetion of tetrecycline. TC concentrations
of blood, liver, kidney and tumor were determined
by modifications of the fluorometric method of
Kohn (27). This method is based upon the finding
that each TC compound forms an extractable
mixed complex, with calcium and barbiturates,
which has a characteristic fluorescent spectrum.
Modifications were aimed at improving tissue re-
coveries of added TC by adopting multiple cx-
traction procedures and by modifying methods of
removing tissue interferents.
Tetracycline-complex activation and fluores-
cence spectra were determined by means of an
Amineo-Buwman spectrophotofluorometer and
Dumont cathode-ray oscilloscope. Aliquots of ex-
tracts were quantitated simultaneously on the
speetrophotofluorometer (at 400 mg A and 530
F) and on an American Instrument Co. Fluoro-
mieropliotometer with a Corning No. 5113 primary
filter and a Corning No. 3486 secondary filter.
Sensitivities of both iustruments were adjusted
(immediately prior to reading) against standard
0.1 x quinine sulfate in 0.1 N H2504.
Because the proteins of blood and tissues bound
TC to differing degrees, it was necessary to con-
struct separate recovery curves I or blood and each
tissue. Mean tissue blanks for each tissue and
blood and their deviations were determined for
both normal and tumorous rats.
nE5ULT5
Tumor evolNtion. An inflammatory response
at the site of application of DMBA was noticed
in the first few weeks. It developed into an
exudative dermatitis with local loss of hair by
four weeks. Despite continued treatment the in-
flammation gradually subsided and had mostly
disappeared by six weeks, but the involved
areas became scaly and thickened. Yerrueous
papules and nodules were visible by the fourth
month, and large tumors had formed by the
fifth or sixth month (Fig. 1). Some tumors
sloughed off, leaving little cancerous tissue in
the ulcerated base.
The types of tumors that developed in 30
DMBA-treated rats w'cre determined. Squa-
mouse cell carcinoma occurred in 27 animals
(90%), two of which also had fibrosareoma
and one had myxosareoma. There were two
examples of sebaoeous carcinoma and one of
pure fibrosareuma. These findings are similar to
those reported by Zaekheim (28).
Tumor fluorescence. Little, if any, fluores-
cence could be detected in 14 intact tumors in
tetracycline-treated rats when examined under
Wood's light. When the tumors were bisected,
gross fluorescence could be seen throughout the
cut surface (+++) in two (Fig. 2), localized
to large nreas (++) in five, localized to small
areas (+) in two, and faint (±) or absent (0)
in five instances. Microscopic fluorescence, on
the other hand, was widely distributed in the
sections (+++) in nine, focal (++) in one,
and in small but detectable amounts (+) in
four tumors. Gross fluorescence did not cor-
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Fm. 1. Bisected squamous ccli carcinoma viewed under daylight
Fxo. 2. Gross fluorescence in a bisected tumor viewed under Wood's light. Compare with
Figure 1.
relate with the microscopy. In one instance,
brilliant fluorescence was recorded by micros-
copy but was absent from the gross specimen
(Table I).
Microscopic sections obtained from tumors
at five (Fig. 3) and 24 hours after TC injection
exhibited a diffuse golden yellow fluorescence.
The fluorescent material in specimens obtained
at 48 and 72 hours was localized in the kerati-
nous tumor cells. It was noted to occur as
particles of various sizes and shapes (Fig. 4, 5).
Sections stored at room temperature for seven
days retained their fluorescence, indicating the
stability of this material. No fluorescence could
be detected in pre-treatment biopsy material or
in tumors from rats that were not given TC.
Comparison of tumor and blood PC conccn-
trations. Figure 6 illustrates the comparative
TC time-concentration curves of blood and tu-
mor, demonstrating that tumor tissue main-
tained a higher level than blood throughout the
entire 72 hour study.
Table II summarizes the results of the spec-
trophotofluorometrie assays of blood, tissues
and tumors of each group of TC injected rats.
TC concentration ratios were calculated to as-
sess the ability of the tissue to differentially
remove the drug from the blood and accumulate
it. These ratios were calculated by dividing the
mean concentrations of TC in tumor, kidney
and liver by the simultaneously determined
mean blood levels and are shown plotted against
time in Fig. 7. By the fifth hour after injection,
the mean tumor TC concentration urns 2.3
1'
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Fro. 3. Fluorescent microscopy (darkfield) of rat sq. cell CA: A, before TC (no fluo-
rescence); B, 5 hours after TC (diffuse fluorescence throughout field). Light microscopy of
approximately same areas, after staining (A 90): C, before TC; D, 5 hours aftcr TC.
Noic similarity in structure; tumor masses in stroma.
TABLE I times the mean blood concentration and, by 24
Tumor fluorescence after TC hours, it was 3 times that of the blood. By 48
hours, when blood TC had fallen to low levels,
Fluorescence Fluorescence the tumor drug concentration was 23 times that
Animal no) post- tumor TC of blood and, by 72 hours, it had reached a
Hours
assay of
inject. Gross Miccoscopical (mcg/gmj coucentration 591 times higher than the blood
103 5 +++ +++ * level.Comparison of tumor and liver TC concen-104 5 ++ ++ 67.17 trations. In the early hours after iujeetion the108 24 ++ +++ 6.12
109 24 4.21 liver appeared to be concentrating TC more
62 48 0 +++ 2.62 than the tumor, as would be expected of an
66 48 + + organ removing a drug for detoxication pur-
105 48 ++ +++ 4.33 poses. At 5 hours, liver concentrations reached
106 48 ++ +++ 0.52 a level more than 13 times that of the blood
107 48 ++ +++ 0.58 (Fig. 7) and 6 times that of the tumor (Fig.
53 72 2.24 8). However, by 24 hours, the period of rapid58 72 + +++ 0.87 detoxieation had passed and the tnmor eon-59 72 1.76
60 72 0 + * centration was then 2.5 times greater than the
64 72 + + + + + + 5.28 liver, which was only slightly higher than the
blood concentration (Fig. 8). By 48 hours, the
*
— Analysis not performed. tumor concentration was 15 times that of the
:
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FIG. 4. Fluorescent microscopy (lightfield) of rat sq. cell Ca: A, before TC; B, 48 hours
after TC. The fluorescent material is localized in keratinizing tumor cells. Light microscopy
of approximately the same fields, after staining (X 89): C, before TC; D, 48 hours after T.
Note the similar tissue pattern of both specimens, consisting of partially keratinized tumor
cells.
Fio. 5. A: Fluorescent material inside keratinizing sq. cell CA cells at 72 hours after TC
(darkfield). B: Same field stained with toluidine blue (X 88).
liver and, at 72 hours, it had not fallen in spite was evident 5 hours post-injection when kidney
of the fact that the blood, liver and kidney TC levels were 6.7 times higher than those in
contained quantities so low as to be barely de- blood (Table II, Fig. 7). Even so, the kidney
tectable. TC eeneentrations were only approximately
Comparison of tumor and kidney TC con- one-half those reached at this time in the liver
cent rations. The excretory phase of the kidney (Fig. 8). Tumor levels were approximately one-
C 
t 
A
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20\
HOURS
Fic. 6. TC time-concentration curves for blood
and tumor compared in the rat.
H OURS
FIG. 7. Tissue/Blood TC concentration ratios
are compared with time. T/B: tumor TC eonc./
blood TC cone.; K: kidney, L: liver.
FIG. 8. Comparison of blood, liver, kidney and
tumor TC concentrations with time.
TABLE II
Summary of results of speclrophotofiuorometric assays in TC injected rats
Hours post-inject.
Blood (mcg/ml)
5 29.9
Mean TC of group
ratios (tissue/blood)
Tissues (meg/gm)
TC Conc.
Tumor
67.2
Liver
408.0
Kidney T/B L/B K/B
199.8 2.3 13.7 6.7
24 1.74 5.2 2.11 6.0 3.0 1.2 3.5
48 0.09 2.0 0.14 0.50 22.9 1.6 5.7
72 0.004 2.5 0 0.06 590.7 0 14.5
580
560
540
520
TC CONC. RATIOS
8—-i) TUMOR/BLOOD
.——-.KIDNEY/BL000
a—.—. LIVER / B LOGS
x ie/000-JUi
(1)
U)
H-
(/)0
H-
6
z00
C)
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third of kidney levels. At 24 hours, kidney con-
centrations were 3.5 times higher than blood
levels but only slightly higher than those in
tumors. At 48 hours, the situation was reversed
with a tumor concentration quadruple that in
the kidney and, by 72 hours, the tumor TC
concentration ratio was 41 times that of the
kidney.
DISCUSSION
The tetracychnes are versatile in their chemi-
cal properties and reactions. They ehelate poly-
valent ions, and their binding to calcium and
magnesium largely determines their localiza-
tion and retention in tissues (29—31). In addi-
tion to this chelating action, it has been sug-
gested that the binding of tetracyelines to
macromolecules, e.g. proteins and peptides, may
be through metal bridge complexes (32).
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Toto (33) found that poorly differentiated,
anaplastic squamous cell carcinomas showed
little or no intercellular mucopolysaccharides,
and that the calcium content of the squamous
cells was decreased. The highly keratinized tu-
mor cells, on the other hand, showed both an
acid polysaccharide matrix and calcium bind-
ing. He concluded that keratinization is a com-
plex process of protein binding with polysac-
charides and mineralization, not unlike enamel
or bone formation.
During the first 24 hours after tetracycline
administration microscopic fluorescence was dif-
fuse throughout the tumor tissue. This was ap-
parently due to permeation of the tissue by
excessive amounts of the drug. The fluorescent
material later became localized inside carcinoma
cells, being most abundant in keratinizing and
kcratinized cells. No fluorescence could be de-
tected in the stroma at 48 and 72 hours, while
sections taken at 72 hours and stored at room
temperature for seven days still retained
fluorescence within the cells. Such stability of
fluorescence suggests protein-binding of tetra-
cycline. Since its known method of binding is
through a divalent metal ion (32), and since
it localizes in keratinized tumor cells, which are
capable of calcium binding in contrast to other
squamous cells which are not (33), it is possible
that the fluorescence of these cells may be due
to a protein-calcium-tetracycline complex.
Using the cup-plate or tube dilution micro-
biological assays of TC, several investigators
have studied the duration of action of single
doses of TC in various species. Finland (34)
and Maynard (35), using a single 7 mg/Kg T.V.
infusion in man, reported that TC was not
detectable in the blood longer than 20—24 hours
after administration. Using a fluorescence mi-
croscope method, Bottiger (36) stated that 48
hours after 100 or 200 mg/Kg TC TM. in mice
and 24 hours after 80 mg/Kg IV. or 80—120
mg/Kg orally, no TC could be demonstrated
in any tissue. Bone was not studied.
A search of the literature failed to reveal
any report of a single dose of TC administered
by any route in any species that was still de-
tectable in the blood, liver or kidneys as long
as 72 hours after administration. We also failed
to detect TC in these tissues when three non-
tumorous rats were sacrificed 72 hours after
receiving an I.P. 60 mg/Kg dose of TC. In spite
of this fact, when the tumor rats received an
identical dose of antibiotic, at 72 hours TC was
detectable in the bloods of three out of four ani-
mals, in the kidneys of three out of five and in
the tumors of four out of four. This suggests
that squamous cell carcinomas can act as TC
depots slowly releasing small amounts of drug
to the blood for excretion over prolonged pe-
riods.
The data indicate that squamous cell car-
cinomas have an affinity for TC and are able
to remove it from blood and retain it for con-
siderable periods. This is evident from the fact
that the tumor tissue maintained a higher TC
level than blood throughout the entire 72 hour
post-injection period and still retained the drug
after it was no longer detectable in the blood.
During the early hours after injection (the ac-
tive detoxication and excretory phase), the
liver and kidney were superior to the tumor in
removing TC from the blood but, by 24 hours,
the tumor contained almost as much TC as the
kidney and 2.5 times as much as the liver. By
72 hours, the tumor TC concentration was 591
times that of the blood, 41 times that of the
kidney and infinitely higher than the liver,
since the liver TC concentration had, by this
time, fallen to zero. The mean tumor TC con-
centration remained just as high (2.5 meg/Gm)
at 72 hours as at 48 (2.0 mcg/Gm). The slow
rate of TC disappearance from the tumors
probably indicates a slowly-reversible protein
binding of TC within the tumor cells.
Poor correlation was noted between the gross
fluorescence of the cut section of the tumor and
its microscopic fluorescence, and between the
latter and the fluorometric analysis. The chemi-
cal estimation was far more sensitive and ac-
curate than microscopy. Fluorometric TC anal-
ysis has an advantage over microbiological
assay in that analysis can be performed without
deterioration of the antibiotic potency such as
occurs during the usual 18 hour incubation pe-
riod at 37 degrees C. required for the growth of
the test organism.
CONCLUSIONS
1. Rat squamous cell carcinomas cumulate
TC, retain it for long periods and slowly re-
lease it, resulting in detectable blood and kid-
ney levels 72 hours after injection, a time when
the drug is no longer detectable in normal ani-
mals.
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2. Gross fluorescence is not reliable in the
detection of malignant tumors.
3. Microscopic fluorescence does not corre-
late well with fluorometric assay and the latter
is more sensitive and accurate.
4. It is suggested that the site of TC fluores-
cence in squamous cell carcinoma in a protein-
calcium-TC complex formed inside the ccli.
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